A retrospective, case-control study of effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant
Latest Information Update: 14 Nov 2022
At a glance
- Drugs Sotrovimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 14 Nov 2022 New trial record
- 01 Nov 2022 Results of sub-group analysis published in the International Journal of Infectious Diseases.